Personalized Medicine Will Require Greater CDER, CDRH Cooperation
Executive Summary
Drug regulation during an era of personalized medicine will require cultural if not structural changes on the part of FDA
You may also be interested in...
“Critical Path” Is On The Road Forward; FDA Reports Industry Activity Is High
The Critical Path Initiative is entering 2007 with growing momentum, bolstered by a new, tailored agency infrastructure and increased industry awareness of FDA's initiative to spur drug development
NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications
New Look At Ezetimibe Fails To Confirm Vytorin Cancer Signal
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.